Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting Karl R Hansen, M.D., Ph.D., Jamie L Morris,

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

Antagonists in poor-responder patients

Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

The normal variabilities of the menstrual cycle

Steven D Spandorfer, M. D. , F Arrendondo-Soberon, M. D. , J. R

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation

Marcos Meseguer, Ph. D. , Rebeca Santiso, Ph. D. , Nicolás Garrido, Ph

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age Sanja Kupesic, M.D., Ph.D., Asim Kurjak,

Dramatic declines in implantation and pregnancy rates in patients who undergo repeated cycles of in vitro fertilization with blastocyst transfer after.

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained.

Biomarkers of ovarian response: current and future applications

The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis Georgina.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis Cui Hong Zheng, M.D., Ph.D.,

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Links between age at menarche, antral follicle count, and body mass index in African American and European American women Sonya M. Schuh, Ph.D., Julia.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

A retrospective study on the use of dose-dependent letrozole to decrease cancer recurrence and adverse events in patients undergoing ovarian stimulation

Bruce S Shapiro, M. D. , Kevin S Richter, Ph. D. , Dee C Harris, M. T

Use of the Antral Follicle Count to Predict the Outcome of Assisted Reproductive Technologies Ming-Yang Chang, Chi-Hsin Chiang, T’sang-T’ang Hsieh, Yung-Kuei.

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist Annika.

Effect of endometriosis on in vitro fertilization

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Amy Criniti, M. D. , Angela Thyer, M. D. , Gregory Chow, M. D

Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.

A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child Xin Chen, M.D., M.Sc., Shi-ling Chen,

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Performance of basal follicle-stimulating hormone and patient's age in the prediction of poor ovarian response and IVF outcome of women who developed.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Brooks A. Keel, Ph.D., H.C.L.D.(A.B.B.) Fertility and Sterility

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes,

Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation Janet F. McLaren, M.D., Richard O. Burney,

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles2

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Superoxide dismutase activity in human follicular fluid after controlled ovarian hyperstimulation in women undergoing in vitro fertilization Luca Sabatini,

Presentation transcript:

Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting Karl R Hansen, M.D., Ph.D., Jamie L Morris, M.D., Angela C Thyer, M.D., Michael R Soules, M.D. Fertility and Sterility Volume 80, Issue 3, Pages 577-583 (September 2003) DOI: 10.1016/S0015-0282(03)00741-6

FIGURE 1 The effect of down-regulation with a GnRH agonist upon antral follicle count. Box plot representation before (A) and after (B) GnRH agonist down-regulation. (Wilcoxon signed-rank test, P=.86, n = 20). Hansen. Variability in antral follicle count.Fertil Steril 2003. Fertility and Sterility 2003 80, 577-583DOI: (10.1016/S0015-0282(03)00741-6)

FIGURE 2 Interobserver variability in antral follicle count. Each bar graph (A–F) represents the mean observed AF count (with one SD error bars) for six independent ovarian ultrasound videotapes reviewed by six blinded observers. The ovarian ultrasounds were arbitrarily ordered from the lowest to the highest AF count. Hansen. Variability in antral follicle count.Fertil Steril 2003. Fertility and Sterility 2003 80, 577-583DOI: (10.1016/S0015-0282(03)00741-6)

FIGURE 3 Intercycle variability in antral follicle count vs. mean antral follicle count. Scatterplot with regression line for the SD vs. mean antral follicle count in infertility patients (n = 50) undergoing two (n = 44) or three (n = 6) IVF cycles within a 1-year interval. Each point represents the mean AF count for a given patient vs. the SD (r = 0.31, P=.029, Spearman correlation coefficient). Hansen. Variability in antral follicle count.Fertil Steril 2003. Fertility and Sterility 2003 80, 577-583DOI: (10.1016/S0015-0282(03)00741-6)

FIGURE 4 Stimulation quality in ART cycles vs. mean antral follicle count. Scatterplots with regression lines for mean number of oocytes, mean peak E2, and mean total gonadotropin dose vs. mean AF count (Spearman correlation coefficients). Hansen. Variability in antral follicle count.Fertil Steril 2003. Fertility and Sterility 2003 80, 577-583DOI: (10.1016/S0015-0282(03)00741-6)